Status and phase
Conditions
Treatments
About
This is a first-in-human phase 1 study of SYNCAR-001 + STK-009 in patients with CD19+ hematologic malignancies.
Full description
SYNCAR-001 + STK-009 is a 2-component human orthogonal (ho) IL-2 receptor-ligand cell therapy consisting of (1) SYNCAR-001, a CD19-directed chimeric antigen receptor T cell (CAR-T) co-expressing an engineered IL-2 beta receptor (hoRb); and (2) STK-009, an engineered pegylated IL-2 cytokine (hoIL-2) selective for hoRb. The study will follow a 3+3 design during dose escalation. Cohort A will enroll subjects to SYNCAR-001 + STK-009 with lymphodepletion. At Dose Level 3, a separate dose escalation cohort will be introduced to enroll subjects to SYNCAR-001 + STK-009 without lymphodepletion (Cohort B). Subsequent dose expansions will enroll subjects at the RP2D for each cohort.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Selected Inclusion Criteria:
Selected Exclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
36 participants in 2 patient groups
Loading...
Central trial contact
Clinical Operations
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal